[The reactogenicity of Heberbiovac-HB vaccine at different doses].
Reactogenicity was measured after applying the Heberbiovac-HB recombinant vaccine against hepatitis B virus to three groups of children aged 6-9 years. The vaccine was derived from yeast cells, administered at doses of 10, 5, and 2.5 g, with a schedule of 0, 1 and 6 months. The overall observed symptomatology was low (12.2%) in the three groups with 10.7%, 13.5%, and 12.3% for 10, 5, and 2.5 g, respectively. The predominant symptoms and signs were febricula (7.0%), local pain (3.1%), and erythema (1.2%). No significant differences were found when making a comparison between groups and sexes. An acceptable reactogenicity of the immunogen was confirmed, thus its use is recommended for the protection against hepatitis B virus.
Díaz González
M
M
Instituto de Medicina Tropical Pedro Kourí.
Navia Molina
O
O
Bravo González
J R
JR
Pedroso Flaquet
P
P
Urbino López
A
A
D002648:Child; D003462:Cuba; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000009:adverse effects; D004306:Dose-Response Relationship, Immunologic; D006509:Hepatitis B / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007273:Injections, Intramuscular; D013997:Time Factors; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000009:adverse effects*
D004274:DNA, Recombinant; D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA; C115360:heberbiovac-HB